Trusopt · DIN 02216205 · 2% · Oph Sol
Limited Use, Reason for Use code 171, 172, 387 required; Health Canada lists this DIN as Cancelled post market since 2025-12-08 — choose a marketed DIN from the same-category list.Discontinued December 8, 2025 · checked November 18, 2026
StatusLimited Use, Reason for Use code 171, 172, 387 required; Health Canada lists this DIN as Cancelled post market since 2025-12-08 — choose a marketed DIN from the same-category list.
Write on scriptone applicable Reason for Use code, 171 or 172 or 387 (criteria below); Health Canada lists this DIN as Cancelled post market since 2025-12-08 — choose a marketed DIN from the same-category list.
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 171, 172, 387
Reason for Use code 171
As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 172
As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 387
For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
Savings card: RxHelp ONE lists Trusopt (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Trusopt · DIN 02216205
Manufacturer: Elvium Life Sciences; listing date 1996-12-19
Health Canada: Cancelled post market since 2025-12-08 · brand TRUSOPT · ATC S01EC03 DORZOLAMIDE · form Solution · route Ophthalmic · ingredients DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 2 % · company Elvium life sciences · schedule Prescription
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02216205)
Source record
DIN 02216205: Trusopt
Raw flags: sec12=Y, sec3=Y
Item: 523600083; group id 623; item number 1590; lccId 00086; manufacturer id ELV
Source form: Oph Sol; strength: 2%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $6.1267; ministry $1.4757
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02216205
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20083
Interchangeable products
Dorzolamide · DIN 02522373 · $1.4757
Jamp-Dorzolamide · DIN 02453347 · $1.4757
Med-Dorzolamide · DIN 02457210 · $1.4757
Sandoz Dorzolamide · DIN 02316307 · $1.4757
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since December 8, 2025 — choose a marketed DIN from the same-category list.